Claims for Patent: 6,867,005

Summary for Patent: 6,867,005

Title:	Method and apparatus for increasing the dynamic range and accuracy of binding assays
Abstract:	This invention relates to methods for increasing the dynamic range and accuracy of assays in which the presence, absence, activity or concentration of a target analyte is assayed by the emission or quenching of a light signal, or by a change (i.e., an evolution or loss) of a light signal in two or more time intervals. In preferred embodiments multiple digitized images are captured at varying times, and the images analyzed to identify captured images within the dynamic range of the assay. The invention further relates to apparati capable of implementing such methods.
Inventor(s):	Keys; Daniel A. (Irvine, CA), Reddy; Parameswara M. (Brea, CA)
Assignee:	Beckman Coulter, Inc. (Fullerton, CA)
Application Number:	10/032,790
Patent Claims:	1. A method for enhancing the dynamic range of an assay of the presence, absence, activity or concentration of two or more target analytes in one or more samples wherein the presence, absence, activity or concentration of said target analytes is assayed by detecting the emission or quenching of a light signal, wherein said method comprises the steps: (A) conducting an assay for the presence, absence, activity or concentration of each of said target analytes in said one or more samples wherein said assays each cause light signals to be emitted or quenched; (B) employing a computer system comprising a CCD camera detector to detect said light signals for an initial detection time duration, and to generate data corresponding to said initially detected signals; and (C) for each target analyte being assayed, independently causing said computer system to compare said generated data-to data corresponding to the light signal generated by a known concentration of said target analyte and to determine whether said detected signal is within the known dynamic range of said detector's ability to assay that target analyte, wherein, for at least one target analyte said initially detected signal is outside the known dynamic range of said detector's assay for said target analyte, and: (1) for each target analyte whose initially detected signal is outside the known dynamic range of said detector's assay for a target analyte, causing said computer system to vary the detection time duration relative to said initial detection time duration until the detected signal for such analyte is within the known dynamic range of said detector's assay for that target analyte, and then causing said computer system to report the presence, absence, activity or concentration of such target analyte; and (2) for each target analyte whose initially detected signal is within the known dynamic range of said detector's assay for a target analyte, causing said computer system to report the presence, absence, activity or concentration of such target analyte; so that, for each target analyte being assayed the presence, absence, activity or concentration of such target analyte is determined using data corresponding to a light signal that is within the dynamic range of said detector's assay for that target analyte. 2. The method of claim 1, wherein said method simultaneously assays the presence, absence, activity or concentration of two or more of said target analytes in said sample. 3. The method of claim 1, wherein said method sequentially assays the presence, absence, activity or concentration of two or more of said target analytes in said sample. 4. The method of claim 1, wherein said step (C) is performed simultaneously for each target analyte being assayed. 5. The method of claim 1, wherein said step (C) is performed sequentially for each target analyte being assayed. 6. The method of claim 1, wherein at least one of said target analyte is selected from the group consisting of an enzyme, a drug or metabolite, a co-factor, a receptor, a receptor ligand, a hormone, a cytokine, a blood factor, a virus, an antigen, a steroid, and an antibody. 7. The method of claim 6, wherein said assay assays the presence, absence, activity or concentration of an enzyme. 8. The method of claim 7, wherein said enzyme is selected from the group consisting of bone specific alkaline phosphatase, aldose reductase, myoglobin, and troponin I. 9. The method of claim 6, wherein said assay assays the presence, absence, activity or concentration of a drug or metabolite. 10. The method of claim 9, wherein said drug or metabolite is selected from the group consisting of: an anti-cancer drug, chemotherapeutic drug, anti-viral drug, non-steroidal anti-inflammatory drug (NSAID), steroidal anti-inflammatory drug, anti-fungal drug, detoxifying drug, analgesic, bronchodilator, anti-bacterial drug, antibiotic drugs, diuretic, digoxin, anti-metabolite, calcium channel blocker, drug for treatment of psoriasis, and a substance of abuse. 11. The method of claim 6, wherein said assay assays the presence, absence, activity or concentration of a co-factor. 12. The method of claim 11, wherein said co-factor is a vitamin, T3, or T4. 13. The method of claim 6, wherein said assay assays the presence, absence, activity or concentration of a cytokine. 14. The method of claim 13, wherein said cytokine is IL-1.beta., IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, TNF.alpha., VEGF, GMCSF, FGF.beta., INF.gamma., EGF, PDGF, MCSF, SCF, insulin, VEGF, Trk, Met, Ron, Axl, Eph, Fas, CD40, CD30, CD27, 4-1BB, LNGFR, OX40, TGF.beta.R, or is a ligand of CCR1, CCR2.alpha., .beta., CCR3, CCR4, CCR5, CXCR1, CXCR2, CXCR3, CXCR4, BLR1, BLR2, or V28 receptor, or is a ligand of a receptor of IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, or IL-13. 15. The method of claim 6, wherein said assay assays the presence, absence, activity or concentration of a receptor or receptor ligand. 16. The method of claim 15, wherein said receptor or receptor ligand is 4-1BB, Axl, BLR1, BLR2, CCR1, CCR2.alpha., .beta., CCR3, CCR4, CCR5, CD27, CD30, CD4, CD4, CD40, CXCR1, CXCR2, CXCR3, CXCR4, EGFR, Eph, EPO receptor, Fas receptor, GCSFR, GHR, GMCSFR.alpha., gp130, IFNgR.alpha., IFNgR.beta., IFN.alpha.R1, insulin-R, IL-1.beta., IL-2R .beta., IL-2R.gamma. chains, IL-4R.alpha., IL-3R.alpha., IL-5R.alpha., IL-6R.alpha., IL-7R.alpha., IL-9R.alpha., IL-10R, IL-11R.alpha., IL-12Rb1, IL-12Rb2, IL-13R.alpha., GMCSFR.alpha., IL-3/L-5/GM-CSF receptor common .beta.-chain, LIFR .beta., LNGFR, MCSFR, Met, OBR, OSMR.beta., OX40, PDGFR, PRL, Ron, SCFR, TPOR, TFR, TGF.beta.R, TNFRI, TNFRII, TPOR, Trk, V28, VEGFR. 17. The method of claim 6, wherein said assay assays the presence, absence, activity or concentration of a hormone. 18. The method of claim 12, wherein said hormone is adrenaline, adrenocorticotropic hormone, testosterone, angiotensinogen, antidiuretic hormone, atrial-natriuretic peptide, calcitonin, calcitriol, cholecystokinin, chorionic gonadotropin, cortisol, dopaniine, erythropoietin, estradiol, follicle-stimulating hormone, gastrin, glucagon, gonadotropin-releasing hormone, gorticotropin-releasing hormone, growth hormone, growth hormone-releasing hormone, insulin, insulin-like growth factor-1, leptin, luteinizing hormone, melatonin, aldosterone, neuropeptide Y, noradrenaline, oxytocin, parathyroid hormone, progesterone, prolactin, renin, secretin, somatostatin, theophylline, thiiodothyronine, thrombopoletin, thyroid-stimulating hormone, thyrotropin-releasing hormone, or thyroxine. 19. The method of claim 6, wherein said assay assays a binding activity of an antigen or an antibody. 20. The method of claim 19, wherein said assay assays a binding activity of an antigen characteristic of Chlamydia, Streptococcus pyogenes Group A bacteria, H. pylori, or M. tuberculosi, hepatitis virus, rubella, CMV, HIV, FIV, or prostate specific antigen, or an antibody elicited in response to any of such antigens. 21. The method of claim 6, wherein said assay assays a binding activity of an autoimmune immunoglobulin, thyroglobulin, anti-thyroglobulin, IgE, IgG, or IgM immunoglobulin. 22. The method of claim 6, wherein said assay assays a binding activity of a tumor marker. 23. The method of claim 1, wherein said light signal is an evolution or loss of a fluorescent light signal. 24. The method of claim 1, wherein said light signal is an evolution or loss of a chemiluminescent light signal. 25. The method of claim 1, wherein said light signal is an evolution or loss of an ultraviolet light signal. 26. The method of claim 1, wherein said light signal is an evolution or loss of a visible wavelength light signal. 27. The method of claim 1, wherein said assays are conducted in a multi-well microtiter plate. 28. The method of claim 1, wherein a target analyte has an activity and wherein said computer system additionally calculates the rate of activity of said target analyte in said sample.

Details for Patent 6,867,005

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2039-03-29
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2039-03-29
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2039-03-29
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2039-03-29
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2039-03-29
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	03/05/1973		2039-03-29